Praxis Precision Medicines Secures Breakthrough Designation After 77% Seizure Reduction
PRAX•Praxis received FDA Breakthrough Therapy Designation for its antisense oligonucleotide elsunersen after the EMBRAVE Part A trial reported a 77% sham-adjusted reduction in monthly seizures (p=0.015) sustained through one-year open-label extension. Elsunersen also holds Orphan Drug and Rare Pediatric Disease FDA designations plus EMA PRIME status, enabling expedited regulatory review.
1. Breakthrough Therapy Designation Granted
The FDA granted Breakthrough Therapy Designation to elsunersen (PRAX-222) for treating seizures associated with SCN2A gain-of-function developmental and epileptic encephalopathy. This third BTD in Praxis’s late-stage pipeline underscores regulatory confidence in its Solidus™ antisense oligonucleotide platform.
2. EMBRAVE Part A Trial Results
In the randomized, sham-controlled EMBRAVE Part A study of nine pediatric patients aged 2–12, elsunersen achieved a 77% sham-adjusted reduction in monthly seizures (p=0.015; 95% CI [33, 92]). Seventy-one percent of patients saw over 50% seizure reduction and 57% experienced at least 28 consecutive seizure-free days, with benefits maintained for up to one year and no drug-related serious adverse events.
3. EMBRAVE3 Registrational Study
Praxis converted its pivotal EMBRAVE3 trial to a single-arm, baseline-controlled design enrolling roughly 30 patients who will receive elsunersen for 24 weeks plus an extension. The primary endpoint is change in countable motor seizures, aligning with an expedited pathway for potential approval.
4. Regulatory Designations and Strategic Impact
Elsunersen holds Orphan Drug and Rare Pediatric Disease designations from the FDA and Orphan Drug plus PRIME status from the EMA. These multiple designations support accelerated development timelines and may enhance valuation by shortening the path to market for this first disease-modifying SCN2A-DEE therapy.
